Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics

被引:44
作者
Niwa, Takashi [1 ,2 ]
Imanishi, Yoshinori [1 ]
Ohmori, Tomofumi [1 ]
Matsuura, Katsuhiko [1 ]
Murakami, Nobuo [2 ]
Itoh, Yoshinori [1 ]
机构
[1] Gifu Univ Hosp, Dept Pharm, Gifu, Japan
[2] Gifu Univ Hosp, Ctr Nutr Support & Infect Control, Gifu, Japan
关键词
Teicoplanin; Optimal concentration; Trough concentration; Initial loading dose; Population pharmacokinetics; CLINICAL PHARMACOKINETICS;
D O I
10.1016/j.ijantimicag.2009.12.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
An initial loading dose of teicoplanin is required to reach the optimal trough concentration (>= 10 mu g/mL) rapidly. To attain the optimal teicoplanin concentration efficiently, an individual loading dose regimen based on population pharmacokinetics, in which the target trough concentration was set to 15 mu g/mL, was defined. Among 70 patients, 33 patients received the individual loading dose regimen, 33 patients received the conventional loading dose regimen (200 mg or 400 mg every 12 h on Day 1 followed by 200 mg once daily) and 4 patients received no loading dose. The proportion of patients showing an optimal plasma concentration was 88% in the individual loading dose regimen but only 33% in the conventional loading dose regimen. No patient without a loading dose showed the optimal concentration. Both total loading dose and plasma concentration were significantly (P < 0.001) higher in the individual loading dose group than in the conventional loading dose group. Notably, the trough concentration was almost constant in patients with individual loading doses ranging from 800 mg to 1800 mg. These findings suggest that individual adjustment of the initial loading dose of teicoplanin is potentially useful to attain the optimal concentration rapidly. (C) 2010 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:507 / 510
页数:4
相关论文
共 15 条
[1]   TEICOPLANIN PHARMACOKINETICS IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
BONATI, M ;
TRAINA, GL ;
VILLA, G ;
SALVADEO, A ;
GENTILE, MG ;
FELLIN, G ;
ROSINA, R ;
CAVENAGHI, L ;
BUNIVA, G .
CLINICAL PHARMACOKINETICS, 1987, 12 (04) :292-301
[2]   Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis [J].
Brink, A. J. ;
Richards, G. A. ;
Cummins, R. R. ;
Lambson, J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (05) :455-458
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   The use and therapeutic drug monitoring of teicoplanin in the UK [J].
Darley, ESR ;
MacGowan, AP .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (01) :62-69
[5]   A RISK-BENEFIT ASSESSMENT OF TEICOPLANIN IN THE TREATMENT OF INFECTIONS [J].
DELALLA, F ;
TRAMARIN, A .
DRUG SAFETY, 1995, 13 (05) :317-328
[6]   Teicoplanin therapy for Staphylococcus aureus septicaemia:: relationship between pre-dose serum concentrations and outcome [J].
Harding, I ;
MacGowan, AP ;
White, LO ;
Darley, ESR ;
Reed, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :835-841
[7]  
Niwa Toshiro, 2004, Japanese Journal of Antibiotics, V57, P413
[8]   Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose [J].
Pea, F ;
Brollo, L ;
Viale, P ;
Pavan, F ;
Furlanut, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) :971-975
[9]   Teicoplanin in patients with acute leukaemia and febrile neutropenia - A special population benefiting from higher dosages [J].
Pea, F ;
Viale, P ;
Candoni, A ;
Pavan, F ;
Pagani, L ;
Damiani, D ;
Casini, M ;
Furlanut, M .
CLINICAL PHARMACOKINETICS, 2004, 43 (06) :405-415
[10]   CLINICAL PHARMACOKINETICS OF TEICOPLANIN [J].
ROWLAND, M .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :184-209